PORTIA: A PHASE 1B STUDY EVALUATING SAFETY AND EFFICACY OF TISAGENLECLEUCEL AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) - Jaeger, U.; McGuirk, J.; Worel, N.; Riedell, P.; Fleury, I.; Borchmann, P.; Forcina, A.; Chu, J.; Leung, M.; Pacaud, L.; Waller, E.